REGENERON PHARMACEUTICALS, INC. (REGN) Free cash flow 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$4.1BFY2025 · since FY2016: $974.0M → $4.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $4.1B | +11.3% |
| FY2024 | $3.7B | -5.4% |
| FY2023 | $3.9B | -12.4% |
| FY2022 | $4.4B | -32.2% |
| FY2021 | $6.5B | +225.9% |
| FY2020 | $2.0B | +0.2% |
| FY2019 | $2.0B | +10.4% |
| FY2018 | $1.8B | +75.2% |
| FY2017 | $1.0B | +6.2% |
| FY2016 | $974.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Net marginREGN Gross profitREGN Gross marginREGN Operating incomeREGN Operating marginREGN Operating cash flowREGN Capital expendituresREGN Return on equityREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Total liabilitiesREGN Shareholders’ equityREGN overview →